An observational study in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-09-12.
Sponsored by Boehringer Ingelheim · Observational
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 346 is above the median of 157 across 929 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with chronic obstructive airways disease recruited at general practitioners, pneumologists, internists
Exclusion Criteria:
Drug: Atrovent® inhalets
Investigator assessment of improvement of the clinical picture rated on a 6-point symptom profile
Time frame: Up to 4 weeks after first drug administration
Assessment of efficacy by investigator on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Assessment of efficacy by patient on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Assessment of tolerability by investigator on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Assessment of tolerability by patient on a 4-point scale
Time frame: Up to 4 weeks after first drug administration
Number of patients with adverse drug reactions
Time frame: Up to 4 weeks after first drug administration
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim